

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



The United Laboratories International Holdings Limited

聯邦制藥國際控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 3933)

**UPDATED INFORMATION ON THE GROUP'S PRODUCT
LEVOFLOXACIN EYE DROPS**

This announcement is made by The United Laboratories International Holdings Limited (the "Company") on a voluntary basis.

The board of directors (the "Board") of the Company is pleased to announce that Levofloxacin Eye Drops (specification: 0.488% (5ml:24.4mg)) submitted by Zhuhai United Laboratories Co., Ltd, Zhongshan Branch, a wholly-owned subsidiary of the Company, have been approved by China National Medical Products Administration, with drug approval number of H20256135.

Levofloxacin is the third-generation quinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, thereby blocking bacterial DNA synthesis. It exhibits significant antibacterial activity against a variety of Gram-positive and Gram-negative bacteria. Levofloxacin eye drops have a broad antibacterial spectrum and strong antimicrobial efficacy, and are widely used clinically for the treatment of blepharitis, hordeolum, dacryocystitis, conjunctivitis, meibomian gland inflammation, and keratitis, as well as for sterilization and chemoprophylaxis during perioperative ophthalmic procedures. Currently, levofloxacin eye drops have been listed in the Category A in the National Medical Insurance Drug List (2024 Edition).

The approval of this product will further expand the Company's ophthalmic portfolio and strengthen the Company's leading position in the field of ophthalmic anti-infective treatment. The Company will continue to advance the development of new products and provide comprehensive, high-quality therapeutic solutions for clinical use, which is expected to generate greater returns for the Company and its shareholders.

By Order of the Board

The United Laboratories International Holdings Limited

Tsoi Hoi Shan

Chairman

Hong Kong, 9 December 2025

As at the date of this announcement, the Board comprises Mr. Tsoi Hoi Shan, Mr. Leung Wing Hon, Ms. Choy Siu Chit, Mr. Fang Yu Ping, Ms. Zou Xian Hong and Ms. Zhu Su Yan as executive directors; and Mr. Chong Peng Oon, Prof. Song Ming and Dr. Fu Qiushi as independent non-executive directors.